医学
寄生菌
不育
子宫内膜异位症
卵胞浆内精子注射
随机对照试验
妇科
怀孕
产科
激素拮抗剂
激素
体外受精
妊娠率
人类受精
不明原因不孕症
男科
促排卵
女性不育
胚胎移植
辅助生殖技术
生理学
控制性卵巢过度刺激
妊娠期
临床试验
作者
Mariam Ahmed Mohamed Dawoud,Ahmed Alhalwagy¹,Rasha Omar Fathy,Mohamed Gamal,Mona Mohamed Sediek
标识
DOI:10.1186/s43043-026-00373-7
摘要
Background Endometriosis-associated infertility may compromise oocyte competence, fertilization, embryo development, and implantation. Hormonal pretreatment with dienogest has been proposed to improve the reproductive environment before intracytoplasmic sperm injection (ICSI), although evidence remains inconsistent. Objective To evaluate the effect of dienogest pretreatment on embryological and pregnancy outcomes in women with endometriosis-associated infertility undergoing their first ICSI cycle. Methods This single-center, open-label, randomized controlled trial was conducted at Kasr Al-Ainy Hospital, Cairo University, between November 2023 and April 2025. It included 86 women aged 20–40 years with endometriosis-associated infertility. Participants were allocated equally to dienogest pretreatment for 3–6 months before ICSI or to direct ICSI without hormonal pretreatment. The number of retrieved oocytes was the primary endpoint on which the sample-size calculation was based. Fertilization rate and number of good-quality embryos were secondary embryological outcomes, while biochemical and clinical pregnancy were secondary pregnancy outcomes. Results The mean number of retrieved oocytes did not differ between groups (unadjusted P = 0.752; Bonferroni-adjusted P = 1.000). The fertilization rate was higher in the dienogest group and remained statistically significant after Bonferroni correction (unadjusted P = 0.001; adjusted P = 0.006). The mean number of good-quality embryos was higher in the dienogest group; however, the difference was not statistically significant after multiplicity adjustment (unadjusted P = 0.011; adjusted P = 0.054). Biochemical pregnancy (48.8% versus 27.9%) and clinical pregnancy (46.5% versus 23.3%) were also numerically higher in the dienogest group, but neither remained statistically significant after Bonferroni correction (adjusted P = 0.230 and P = 0.118, respectively). Conclusion Dienogest pretreatment was associated with improved fertilization, while no clear differences were observed in the other evaluated reproductive outcomes. These findings are limited to intermediate embryological and early pregnancy outcomes; live birth was not assessed. Trial Registration ClinicalTrials.gov identifier: NCT06577974. The trial was retrospectively registered on 16 August 2024 and publicly posted on 29 August 2024.
科研通智能强力驱动
Strongly Powered by AbleSci AI